Sanofi Regeneron Report Phase 3 ODYSSEY MONO trial with Alirocumab Met Primary Efficacy Endpoint

Sanofi (NYSE: SNY ) and Regeneron Pharmaceuticals (NASDAQ: REGN ) today announced that the Phase 3 ODYSSEY MONO trial with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), met its primary efficacy endpoint. The mean low-density lipoprotein-cholesterol (LDL-C, or "bad" cholesterol) reduction from baseline